#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Synthetic lethality has immense potential in cancer therapeutics .
3-1	15-24	Synthetic	abstract[3]	new[3]	coref	5-12[0_3]
3-2	25-34	lethality	abstract[3]	new[3]	_	_
3-3	35-38	has	_	_	_	_
3-4	39-46	immense	abstract[4]	new[4]	_	_
3-5	47-56	potential	abstract[4]	new[4]	_	_
3-6	57-59	in	abstract[4]	new[4]	_	_
3-7	60-66	cancer	abstract[4]|abstract|abstract[6]	new[4]|new|new[6]	coref|coref	6-24|6-24
3-8	67-79	therapeutics	abstract[4]|abstract[6]	new[4]|new[6]	_	_
3-9	80-81	.	_	_	_	_

#Text=Where the driver genes or oncogenes cannot be targeted , synthetic lethal interactors can potentially serve as drug targets in the presence of mutations in the driver genes , as the mutant tumor cells are dependent upon the synthetic lethal interactors for their survival .
4-1	82-87	Where	_	_	_	_
4-2	88-91	the	abstract[8]	new[8]	coref	4-26[15_8]
4-3	92-98	driver	person|abstract[8]	new|new[8]	coref	4-27
4-4	99-104	genes	abstract[8]	new[8]	_	_
4-5	105-107	or	_	_	_	_
4-6	108-117	oncogenes	abstract	new	ana	4-43
4-7	118-124	cannot	_	_	_	_
4-8	125-127	be	_	_	_	_
4-9	128-136	targeted	_	_	_	_
4-10	137-138	,	_	_	_	_
4-11	139-148	synthetic	abstract[10]	new[10]	coref	4-38[18_10]
4-12	149-155	lethal	abstract[10]	new[10]	_	_
4-13	156-167	interactors	abstract[10]	new[10]	_	_
4-14	168-171	can	_	_	_	_
4-15	172-183	potentially	_	_	_	_
4-16	184-189	serve	_	_	_	_
4-17	190-192	as	_	_	_	_
4-18	193-197	drug	substance	new	coref	6-20
4-19	198-205	targets	_	_	_	_
4-20	206-208	in	_	_	_	_
4-21	209-212	the	abstract[12]	new[12]	_	_
4-22	213-221	presence	abstract[12]	new[12]	_	_
4-23	222-224	of	abstract[12]	new[12]	_	_
4-24	225-234	mutations	abstract[12]|abstract[13]	new[12]|new[13]	coref	15-11[134_13]
4-25	235-237	in	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-26	238-241	the	abstract[12]|abstract[13]|abstract[15]	new[12]|new[13]|giv[15]	coref	5-15[27_15]
4-27	242-248	driver	abstract[12]|abstract[13]|person|abstract[15]	new[12]|new[13]|giv|giv[15]	_	_
4-28	249-254	genes	abstract[12]|abstract[13]|abstract[15]	new[12]|new[13]|giv[15]	_	_
4-29	255-256	,	_	_	_	_
4-30	257-259	as	_	_	_	_
4-31	260-263	the	object[17]	new[17]	coref	19-21[180_17]
4-32	264-270	mutant	object[17]	new[17]	_	_
4-33	271-276	tumor	abstract|object[17]	new|new[17]	coref	8-47
4-34	277-282	cells	object[17]	new[17]	_	_
4-35	283-286	are	_	_	_	_
4-36	287-296	dependent	_	_	_	_
4-37	297-301	upon	_	_	_	_
4-38	302-305	the	abstract[18]	giv[18]	coref	9-11[71_18]
4-39	306-315	synthetic	abstract[18]	giv[18]	_	_
4-40	316-322	lethal	abstract[18]	giv[18]	_	_
4-41	323-334	interactors	abstract[18]	giv[18]	_	_
4-42	335-338	for	abstract[18]	giv[18]	_	_
4-43	339-344	their	abstract[18]|abstract|abstract[20]	giv[18]|giv|new[20]	_	_
4-44	345-353	survival	abstract[18]|abstract[20]	giv[18]|new[20]	_	_
4-45	354-355	.	_	_	_	_

#Text=Recent advances in RNAi and CRISPR technologies have enabled large-scale synthetic lethality screens for individual genes to be performed in human cell lines .
5-1	356-362	Recent	abstract[21]	new[21]	_	_
5-2	363-371	advances	abstract[21]	new[21]	_	_
5-3	372-374	in	abstract[21]	new[21]	_	_
5-4	375-379	RNAi	abstract[21]|abstract	new[21]|new	_	_
5-5	380-383	and	abstract[21]	new[21]	_	_
5-6	384-390	CRISPR	abstract[21]|abstract	new[21]|new	_	_
5-7	391-403	technologies	abstract[21]|abstract	new[21]|new	_	_
5-8	404-408	have	_	_	_	_
5-9	409-416	enabled	_	_	_	_
5-10	417-428	large-scale	abstract[26]	new[26]	coref	8-24[61_26]
5-11	429-438	synthetic	abstract[26]	new[26]	_	_
5-12	439-448	lethality	abstract|abstract[26]	giv|new[26]	coref	12-12[103_0]
5-13	449-456	screens	abstract[26]	new[26]	_	_
5-14	457-460	for	abstract[26]	new[26]	_	_
5-15	461-471	individual	abstract[26]|abstract[27]	new[26]|giv[27]	coref	9-15[73_27]
5-16	472-477	genes	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
5-17	478-480	to	_	_	_	_
5-18	481-483	be	_	_	_	_
5-19	484-493	performed	_	_	_	_
5-20	494-496	in	_	_	_	_
5-21	497-502	human	object[29]	new[29]	coref	6-24[41_29]
5-22	503-507	cell	place|object[29]	new|new[29]	coref	6-25
5-23	508-513	lines	object[29]	new[29]	_	_
5-24	514-515	.	_	_	_	_

#Text=The genetic dependency map ( DepMap ) project is dedicated towards finding genetic dependencies from the published shRNA/CRISPR or drug screening data in cancer cell lines .
6-1	516-519	The	abstract[31]	new[31]	appos	6-6[0_31]
6-2	520-527	genetic	abstract[31]	new[31]	_	_
6-3	528-538	dependency	abstract|abstract[31]	new|new[31]	_	_
6-4	539-542	map	abstract[31]	new[31]	_	_
6-5	543-544	(	_	_	_	_
6-6	545-551	DepMap	abstract	giv	_	_
6-7	552-553	)	_	_	_	_
6-8	554-561	project	abstract	new	_	_
6-9	562-564	is	_	_	_	_
6-10	565-574	dedicated	_	_	_	_
6-11	575-582	towards	_	_	_	_
6-12	583-590	finding	_	_	_	_
6-13	591-598	genetic	abstract[34]	new[34]	coref	7-3[42_34]
6-14	599-611	dependencies	abstract[34]	new[34]	_	_
6-15	612-616	from	_	_	_	_
6-16	617-620	the	abstract[35]	new[35]	_	_
6-17	621-630	published	abstract[35]	new[35]	_	_
6-18	631-643	shRNA/CRISPR	abstract[35]	new[35]	_	_
6-19	644-646	or	_	_	_	_
6-20	647-651	drug	substance|abstract[38]	giv|new[38]	coref|coref|coref|coref	8-46[67_38]|11-21|8-46[67_38]|11-21
6-21	652-661	screening	abstract|abstract[38]	new|new[38]	coref	11-22
6-22	662-666	data	abstract[38]	new[38]	_	_
6-23	667-669	in	abstract[38]	new[38]	_	_
6-24	670-676	cancer	abstract[38]|abstract|object[41]	new[38]|giv|giv[41]	coref|coref|coref|coref	7-21|11-25[98_41]|7-21|11-25[98_41]
6-25	677-681	cell	abstract[38]|place|object[41]	new[38]|giv|giv[41]	coref	11-26
6-26	682-687	lines	abstract[38]|object[41]	new[38]|giv[41]	_	_
6-27	688-689	.	_	_	_	_

#Text=While identifying genetic dependencies or essentiality in the context of specific genetic alterations is important for screening potential targets for cancer therapy , identification of clinically relevant synthetic lethal pairs in cancers has been a challenge .
7-1	690-695	While	_	_	_	_
7-2	696-707	identifying	_	_	_	_
7-3	708-715	genetic	abstract[42]	giv[42]	_	_
7-4	716-728	dependencies	abstract[42]	giv[42]	_	_
7-5	729-731	or	abstract[42]	giv[42]	_	_
7-6	732-744	essentiality	abstract[42]|abstract	giv[42]|new	_	_
7-7	745-747	in	_	_	_	_
7-8	748-751	the	abstract[44]	new[44]	_	_
7-9	752-759	context	abstract[44]	new[44]	_	_
7-10	760-762	of	abstract[44]	new[44]	_	_
7-11	763-771	specific	abstract[44]|abstract[45]	new[44]|new[45]	_	_
7-12	772-779	genetic	abstract[44]|abstract[45]	new[44]|new[45]	_	_
7-13	780-791	alterations	abstract[44]|abstract[45]	new[44]|new[45]	_	_
7-14	792-794	is	_	_	_	_
7-15	795-804	important	_	_	_	_
7-16	805-808	for	_	_	_	_
7-17	809-818	screening	_	_	_	_
7-18	819-828	potential	abstract[46]	new[46]	coref	12-16[105_46]
7-19	829-836	targets	abstract[46]	new[46]	_	_
7-20	837-840	for	abstract[46]	new[46]	_	_
7-21	841-847	cancer	abstract[46]|abstract|event[48]	new[46]|giv|new[48]	coref|coref	9-16|9-16
7-22	848-855	therapy	abstract[46]|event[48]	new[46]|new[48]	_	_
7-23	856-857	,	_	_	_	_
7-24	858-872	identification	abstract[49]	new[49]	coref	7-35[52_49]
7-25	873-875	of	abstract[49]	new[49]	_	_
7-26	876-886	clinically	abstract[49]|plant[50]	new[49]|new[50]	_	_
7-27	887-895	relevant	abstract[49]|plant[50]	new[49]|new[50]	_	_
7-28	896-905	synthetic	abstract[49]|plant[50]	new[49]|new[50]	_	_
7-29	906-912	lethal	abstract[49]|plant[50]	new[49]|new[50]	_	_
7-30	913-918	pairs	abstract[49]|plant[50]	new[49]|new[50]	_	_
7-31	919-921	in	abstract[49]|plant[50]	new[49]|new[50]	_	_
7-32	922-929	cancers	abstract[49]|plant[50]|abstract	new[49]|new[50]|new	coref	21-10
7-33	930-933	has	_	_	_	_
7-34	934-938	been	_	_	_	_
7-35	939-940	a	abstract[52]	giv[52]	_	_
7-36	941-950	challenge	abstract[52]	giv[52]	_	_
7-37	951-952	.	_	_	_	_

#Text=A recent work tried to address this limitation with an in silico analysis of clinical relevance of the SL interactions identified from in vitro SL screens and reported that only a fraction of these SL interactions hold up to be clinically significant when tested on TCGA tumor data .
8-1	953-954	A	abstract[53]	new[53]	_	_
8-2	955-961	recent	abstract[53]	new[53]	_	_
8-3	962-966	work	abstract[53]	new[53]	_	_
8-4	967-972	tried	_	_	_	_
8-5	973-975	to	_	_	_	_
8-6	976-983	address	_	_	_	_
8-7	984-988	this	abstract[54]	new[54]	_	_
8-8	989-999	limitation	abstract[54]	new[54]	_	_
8-9	1000-1004	with	_	_	_	_
8-10	1005-1007	an	abstract[56]	new[56]	_	_
8-11	1008-1010	in	abstract[56]	new[56]	_	_
8-12	1011-1017	silico	place|abstract[56]	new|new[56]	coref	11-12
8-13	1018-1026	analysis	abstract[56]	new[56]	_	_
8-14	1027-1029	of	abstract[56]	new[56]	_	_
8-15	1030-1038	clinical	abstract[56]|abstract[57]	new[56]|new[57]	ana	9-3[68_57]
8-16	1039-1048	relevance	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-17	1049-1051	of	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-18	1052-1055	the	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	coref	8-34[64_59]
8-19	1056-1058	SL	abstract[56]|abstract[57]|abstract|abstract[59]	new[56]|new[57]|new|new[59]	coref	8-35
8-20	1059-1071	interactions	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	_	_
8-21	1072-1082	identified	_	_	_	_
8-22	1083-1087	from	_	_	_	_
8-23	1088-1090	in	_	_	_	_
8-24	1091-1096	vitro	abstract[61]	giv[61]	coref	9-5[70_61]
8-25	1097-1099	SL	person|abstract[61]	new|giv[61]	coref	14-22
8-26	1100-1107	screens	abstract[61]	giv[61]	_	_
8-27	1108-1111	and	_	_	_	_
8-28	1112-1120	reported	_	_	_	_
8-29	1121-1125	that	_	_	_	_
8-30	1126-1130	only	quantity[62]	new[62]	_	_
8-31	1131-1132	a	quantity[62]	new[62]	_	_
8-32	1133-1141	fraction	quantity[62]	new[62]	_	_
8-33	1142-1144	of	quantity[62]	new[62]	_	_
8-34	1145-1150	these	quantity[62]|abstract[64]	new[62]|giv[64]	coref	11-5[88_64]
8-35	1151-1153	SL	quantity[62]|abstract|abstract[64]	new[62]|giv|giv[64]	coref	11-5
8-36	1154-1166	interactions	quantity[62]|abstract[64]	new[62]|giv[64]	_	_
8-37	1167-1171	hold	_	_	_	_
8-38	1172-1174	up	_	_	_	_
8-39	1175-1177	to	_	_	_	_
8-40	1178-1180	be	_	_	_	_
8-41	1181-1191	clinically	_	_	_	_
8-42	1192-1203	significant	_	_	_	_
8-43	1204-1208	when	_	_	_	_
8-44	1209-1215	tested	_	_	_	_
8-45	1216-1218	on	_	_	_	_
8-46	1219-1223	TCGA	abstract|abstract[67]	new|giv[67]	coref|coref	10-16[0_67]|10-16[0_67]
8-47	1224-1229	tumor	abstract|abstract[67]	giv|giv[67]	coref	20-15
8-48	1230-1234	data	abstract[67]	giv[67]	_	_
8-49	1235-1236	.	_	_	_	_

#Text=Also , these in vitro screens are costly and finding synthetic lethal interactors for many cancer genes remain challenging .
9-1	1237-1241	Also	_	_	_	_
9-2	1242-1243	,	_	_	_	_
9-3	1244-1249	these	abstract[68]	giv[68]	coref	10-30[84_68]
9-4	1250-1252	in	abstract[68]	giv[68]	_	_
9-5	1253-1258	vitro	abstract[68]|organization|abstract[70]	giv[68]|new|giv[70]	_	_
9-6	1259-1266	screens	abstract[68]|abstract[70]	giv[68]|giv[70]	_	_
9-7	1267-1270	are	_	_	_	_
9-8	1271-1277	costly	_	_	_	_
9-9	1278-1281	and	_	_	_	_
9-10	1282-1289	finding	_	_	_	_
9-11	1290-1299	synthetic	abstract[71]	giv[71]	coref	18-12[172_71]
9-12	1300-1306	lethal	abstract[71]	giv[71]	_	_
9-13	1307-1318	interactors	abstract[71]	giv[71]	_	_
9-14	1319-1322	for	abstract[71]	giv[71]	_	_
9-15	1323-1327	many	abstract[71]|abstract[73]	giv[71]|giv[73]	coref	10-24[83_73]
9-16	1328-1334	cancer	abstract[71]|abstract|abstract[73]	giv[71]|giv|giv[73]	coref	10-14
9-17	1335-1340	genes	abstract[71]|abstract[73]	giv[71]|giv[73]	_	_
9-18	1341-1347	remain	_	_	_	_
9-19	1348-1359	challenging	_	_	_	_
9-20	1360-1361	.	_	_	_	_

#Text=SL-BioDP addresses such problems by using a computational method that leverages the available cancer genetic data resources to predict synthetic lethal partners of all cancer susceptibility genes and assesses the clinical relevance from matched clinical data .
10-1	1362-1370	SL-BioDP	abstract	new	coref	12-1
10-2	1371-1380	addresses	_	_	_	_
10-3	1381-1385	such	abstract[75]	new[75]	_	_
10-4	1386-1394	problems	abstract[75]	new[75]	_	_
10-5	1395-1397	by	_	_	_	_
10-6	1398-1403	using	_	_	_	_
10-7	1404-1405	a	abstract[76]	new[76]	_	_
10-8	1406-1419	computational	abstract[76]	new[76]	_	_
10-9	1420-1426	method	abstract[76]	new[76]	_	_
10-10	1427-1431	that	_	_	_	_
10-11	1432-1441	leverages	_	_	_	_
10-12	1442-1445	the	abstract[79]	new[79]	coref	14-4[119_79]
10-13	1446-1455	available	abstract[79]	new[79]	_	_
10-14	1456-1462	cancer	abstract|abstract[79]	giv|new[79]	coref	10-25
10-15	1463-1470	genetic	abstract[79]	new[79]	_	_
10-16	1471-1475	data	abstract|abstract[79]	giv|new[79]	coref	10-34[85_0]
10-17	1476-1485	resources	abstract[79]	new[79]	_	_
10-18	1486-1488	to	_	_	_	_
10-19	1489-1496	predict	_	_	_	_
10-20	1497-1506	synthetic	abstract[80]	new[80]	_	_
10-21	1507-1513	lethal	abstract[80]	new[80]	_	_
10-22	1514-1522	partners	abstract[80]	new[80]	_	_
10-23	1523-1525	of	abstract[80]	new[80]	_	_
10-24	1526-1529	all	abstract[80]|abstract[83]	new[80]|giv[83]	coref	13-15[114_83]
10-25	1530-1536	cancer	abstract[80]|abstract|abstract[83]	new[80]|giv|giv[83]	coref	11-25
10-26	1537-1551	susceptibility	abstract[80]|abstract|abstract[83]	new[80]|new|giv[83]	_	_
10-27	1552-1557	genes	abstract[80]|abstract[83]	new[80]|giv[83]	_	_
10-28	1558-1561	and	_	_	_	_
10-29	1562-1570	assesses	_	_	_	_
10-30	1571-1574	the	abstract[84]	giv[84]	coref	14-16[123_84]
10-31	1575-1583	clinical	abstract[84]	giv[84]	_	_
10-32	1584-1593	relevance	abstract[84]	giv[84]	_	_
10-33	1594-1598	from	abstract[84]	giv[84]	_	_
10-34	1599-1606	matched	abstract[84]|abstract[85]	giv[84]|giv[85]	coref	11-21[95_85]
10-35	1607-1615	clinical	abstract[84]|abstract[85]	giv[84]|giv[85]	_	_
10-36	1616-1620	data	abstract[84]|abstract[85]	giv[84]|giv[85]	_	_
10-37	1621-1622	.	_	_	_	_

#Text=The computational predictions of SL interactions were subjected to extensive in silico validation using either published literature or shRNA and drug screening data from cancer cell lines .
11-1	1623-1626	The	abstract[86]	new[86]	_	_
11-2	1627-1640	computational	abstract[86]	new[86]	_	_
11-3	1641-1652	predictions	abstract[86]	new[86]	_	_
11-4	1653-1655	of	abstract[86]	new[86]	_	_
11-5	1656-1658	SL	abstract[86]|abstract|abstract[88]	new[86]|giv|giv[88]	coref|coref	18-14|18-14
11-6	1659-1671	interactions	abstract[86]|abstract[88]	new[86]|giv[88]	_	_
11-7	1672-1676	were	_	_	_	_
11-8	1677-1686	subjected	_	_	_	_
11-9	1687-1689	to	_	_	_	_
11-10	1690-1699	extensive	_	_	_	_
11-11	1700-1702	in	_	_	_	_
11-12	1703-1709	silico	place|abstract[90]	giv|new[90]	_	_
11-13	1710-1720	validation	abstract[90]	new[90]	_	_
11-14	1721-1726	using	_	_	_	_
11-15	1727-1733	either	abstract[91]	new[91]	coref	21-14[0_91]
11-16	1734-1743	published	abstract[91]	new[91]	_	_
11-17	1744-1754	literature	abstract[91]	new[91]	_	_
11-18	1755-1757	or	_	_	_	_
11-19	1758-1763	shRNA	substance	new	_	_
11-20	1764-1767	and	_	_	_	_
11-21	1768-1772	drug	substance|abstract[95]	giv|giv[95]	coref|coref|coref|coref	12-17|16-4[142_95]|12-17|16-4[142_95]
11-22	1773-1782	screening	abstract|abstract[95]	giv|giv[95]	coref	16-6
11-23	1783-1787	data	abstract[95]	giv[95]	_	_
11-24	1788-1792	from	abstract[95]	giv[95]	_	_
11-25	1793-1799	cancer	abstract[95]|abstract|object[98]	giv[95]|giv|giv[98]	coref|coref|coref|coref	13-15|16-13[146_98]|13-15|16-13[146_98]
11-26	1800-1804	cell	abstract[95]|place|object[98]	giv[95]|giv|giv[98]	coref	16-15
11-27	1805-1810	lines	abstract[95]|object[98]	giv[95]|giv[98]	_	_
11-28	1811-1812	.	_	_	_	_

#Text=SL-BioDP is a comprehensive resource for the query and visualization of cancer-specific synthetic lethality and potential drug targets based on the concept of synthetic lethality .
12-1	1813-1821	SL-BioDP	abstract	giv	coref	12-3[100_0]
12-2	1822-1824	is	_	_	_	_
12-3	1825-1826	a	abstract[100]	giv[100]	coref	14-12[0_100]
12-4	1827-1840	comprehensive	abstract[100]	giv[100]	_	_
12-5	1841-1849	resource	abstract[100]	giv[100]	_	_
12-6	1850-1853	for	abstract[100]	giv[100]	_	_
12-7	1854-1857	the	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
12-8	1858-1863	query	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
12-9	1864-1867	and	abstract[100]	giv[100]	_	_
12-10	1868-1881	visualization	abstract[100]|abstract[102]	giv[100]|new[102]	_	_
12-11	1882-1884	of	abstract[100]|abstract[102]	giv[100]|new[102]	_	_
12-12	1885-1900	cancer-specific	abstract[100]|abstract[102]|abstract[103]	giv[100]|new[102]|giv[103]	coref	12-24[107_103]
12-13	1901-1910	synthetic	abstract[100]|abstract[102]|abstract[103]	giv[100]|new[102]|giv[103]	_	_
12-14	1911-1920	lethality	abstract[100]|abstract[102]|abstract[103]	giv[100]|new[102]|giv[103]	_	_
12-15	1921-1924	and	abstract[100]|abstract[102]	giv[100]|new[102]	_	_
12-16	1925-1934	potential	abstract[100]|abstract[102]|abstract[105]	giv[100]|new[102]|giv[105]	coref	16-18[148_105]
12-17	1935-1939	drug	abstract[100]|abstract[102]|substance|abstract[105]	giv[100]|new[102]|giv|giv[105]	coref	15-4
12-18	1940-1947	targets	abstract[100]|abstract[102]|abstract[105]	giv[100]|new[102]|giv[105]	_	_
12-19	1948-1953	based	_	_	_	_
12-20	1954-1956	on	_	_	_	_
12-21	1957-1960	the	abstract[106]	new[106]	coref	22-21[214_106]
12-22	1961-1968	concept	abstract[106]	new[106]	_	_
12-23	1969-1971	of	abstract[106]	new[106]	_	_
12-24	1972-1981	synthetic	abstract[106]|abstract[107]	new[106]|giv[107]	ana	13-9[0_107]
12-25	1982-1991	lethality	abstract[106]|abstract[107]	new[106]|giv[107]	_	_
12-26	1992-1993	.	_	_	_	_

#Text=The utility of this web tool is that it enables multilevel querying based on cancer genes , tissues , or drugs of interest .
13-1	1994-1997	The	abstract[108]	new[108]	_	_
13-2	1998-2005	utility	abstract[108]	new[108]	_	_
13-3	2006-2008	of	abstract[108]	new[108]	_	_
13-4	2009-2013	this	abstract[108]|object[110]	new[108]|new[110]	_	_
13-5	2014-2017	web	abstract[108]|abstract|object[110]	new[108]|new|new[110]	_	_
13-6	2018-2022	tool	abstract[108]|object[110]	new[108]|new[110]	_	_
13-7	2023-2025	is	_	_	_	_
13-8	2026-2030	that	_	_	_	_
13-9	2031-2033	it	abstract	giv	coref	14-9[120_0]
13-10	2034-2041	enables	_	_	_	_
13-11	2042-2052	multilevel	abstract[112]	new[112]	_	_
13-12	2053-2061	querying	abstract[112]	new[112]	_	_
13-13	2062-2067	based	_	_	_	_
13-14	2068-2070	on	_	_	_	_
13-15	2071-2077	cancer	abstract|abstract[114]	giv|giv[114]	coref|coref|coref|coref	15-13[135_114]|16-14|15-13[135_114]|16-14
13-16	2078-2083	genes	abstract[114]	giv[114]	_	_
13-17	2084-2085	,	abstract[114]	giv[114]	_	_
13-18	2086-2093	tissues	abstract[114]|abstract	giv[114]|new	_	_
13-19	2094-2095	,	abstract[114]	giv[114]	_	_
13-20	2096-2098	or	abstract[114]	giv[114]	_	_
13-21	2099-2104	drugs	abstract[114]|substance[116]	giv[114]|new[116]	coref	18-10[0_116]
13-22	2105-2107	of	abstract[114]|substance[116]	giv[114]|new[116]	_	_
13-23	2108-2116	interest	abstract[114]|substance[116]	giv[114]|new[116]	_	_
13-24	2117-2118	.	_	_	_	_

#Text=In contrast to the other database resources on synthetic lethality , SL-BioDP enables assessment of the clinical relevance of targeting the SL interactor gene in the presence of mutation in the primary gene .
14-1	2119-2121	In	_	_	_	_
14-2	2122-2130	contrast	abstract[117]	new[117]	_	_
14-3	2131-2133	to	abstract[117]	new[117]	_	_
14-4	2134-2137	the	abstract[117]|abstract[119]	new[117]|giv[119]	_	_
14-5	2138-2143	other	abstract[117]|abstract[119]	new[117]|giv[119]	_	_
14-6	2144-2152	database	abstract[117]|abstract|abstract[119]	new[117]|new|giv[119]	_	_
14-7	2153-2162	resources	abstract[117]|abstract[119]	new[117]|giv[119]	_	_
14-8	2163-2165	on	abstract[117]|abstract[119]	new[117]|giv[119]	_	_
14-9	2166-2175	synthetic	abstract[117]|abstract[119]|abstract[120]	new[117]|giv[119]|giv[120]	coref	22-24[215_120]
14-10	2176-2185	lethality	abstract[117]|abstract[119]|abstract[120]	new[117]|giv[119]|giv[120]	_	_
14-11	2186-2187	,	_	_	_	_
14-12	2188-2196	SL-BioDP	abstract	giv	coref	15-22
14-13	2197-2204	enables	_	_	_	_
14-14	2205-2215	assessment	abstract[122]	new[122]	_	_
14-15	2216-2218	of	abstract[122]	new[122]	_	_
14-16	2219-2222	the	abstract[122]|abstract[123]	new[122]|giv[123]	coref	22-29[216_123]
14-17	2223-2231	clinical	abstract[122]|abstract[123]	new[122]|giv[123]	_	_
14-18	2232-2241	relevance	abstract[122]|abstract[123]	new[122]|giv[123]	_	_
14-19	2242-2244	of	_	_	_	_
14-20	2245-2254	targeting	_	_	_	_
14-21	2255-2258	the	abstract[126]	new[126]	coref	14-31[129_126]
14-22	2259-2261	SL	person|abstract[126]	giv|new[126]	_	_
14-23	2262-2272	interactor	person|abstract[126]	new|new[126]	_	_
14-24	2273-2277	gene	abstract[126]	new[126]	_	_
14-25	2278-2280	in	_	_	_	_
14-26	2281-2284	the	abstract[127]	new[127]	_	_
14-27	2285-2293	presence	abstract[127]	new[127]	_	_
14-28	2294-2296	of	abstract[127]	new[127]	_	_
14-29	2297-2305	mutation	abstract[127]|abstract	new[127]|new	coref	16-10
14-30	2306-2308	in	abstract[127]	new[127]	_	_
14-31	2309-2312	the	abstract[127]|abstract[129]	new[127]|giv[129]	coref	16-40[157_129]
14-32	2313-2320	primary	abstract[127]|abstract[129]	new[127]|giv[129]	_	_
14-33	2321-2325	gene	abstract[127]|abstract[129]	new[127]|giv[129]	_	_
14-34	2326-2327	.	_	_	_	_

#Text=The prediction of drug response depending on the presence of mutations in the primary genes is another important feature added in SL-BioDP .
15-1	2328-2331	The	abstract[130]	new[130]	coref	15-17[136_130]
15-2	2332-2342	prediction	abstract[130]	new[130]	_	_
15-3	2343-2345	of	abstract[130]	new[130]	_	_
15-4	2346-2350	drug	abstract[130]|substance|abstract[132]	new[130]|giv|new[132]	coref|coref	16-5|16-5
15-5	2351-2359	response	abstract[130]|abstract[132]	new[130]|new[132]	_	_
15-6	2360-2369	depending	abstract[130]	new[130]	_	_
15-7	2370-2372	on	abstract[130]	new[130]	_	_
15-8	2373-2376	the	abstract[130]|abstract[133]	new[130]|new[133]	_	_
15-9	2377-2385	presence	abstract[130]|abstract[133]	new[130]|new[133]	_	_
15-10	2386-2388	of	abstract[130]|abstract[133]	new[130]|new[133]	_	_
15-11	2389-2398	mutations	abstract[130]|abstract[133]|abstract[134]	new[130]|new[133]|giv[134]	_	_
15-12	2399-2401	in	abstract[130]|abstract[133]|abstract[134]	new[130]|new[133]|giv[134]	_	_
15-13	2402-2405	the	abstract[130]|abstract[133]|abstract[134]|abstract[135]	new[130]|new[133]|giv[134]|giv[135]	_	_
15-14	2406-2413	primary	abstract[130]|abstract[133]|abstract[134]|abstract[135]	new[130]|new[133]|giv[134]|giv[135]	_	_
15-15	2414-2419	genes	abstract[130]|abstract[133]|abstract[134]|abstract[135]	new[130]|new[133]|giv[134]|giv[135]	_	_
15-16	2420-2422	is	_	_	_	_
15-17	2423-2430	another	abstract[136]	giv[136]	_	_
15-18	2431-2440	important	abstract[136]	giv[136]	_	_
15-19	2441-2448	feature	abstract[136]	giv[136]	_	_
15-20	2449-2454	added	_	_	_	_
15-21	2455-2457	in	_	_	_	_
15-22	2458-2466	SL-BioDP	abstract	giv	coref	20-9
15-23	2467-2468	.	_	_	_	_

#Text=Our analysis of published drug screening data and gene mutation data from matched cancer cell lines identified known synthetic lethality-based drug targets like sensitivity of the drug , olaparib ( PARP inhibitor ) in the presence of mutation in the BRCA1 gene , and in general the homologous recombination repair pathway .
16-1	2469-2472	Our	person|abstract[139]	acc|new[139]	coref|ana|coref|ana	17-4[162_139]|18-1|17-4[162_139]|18-1
16-2	2473-2481	analysis	abstract[139]	new[139]	_	_
16-3	2482-2484	of	abstract[139]	new[139]	_	_
16-4	2485-2494	published	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
16-5	2495-2499	drug	abstract[139]|substance|abstract[142]	new[139]|giv|giv[142]	coref	16-21
16-6	2500-2509	screening	abstract[139]|abstract|abstract[142]	new[139]|giv|giv[142]	_	_
16-7	2510-2514	data	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
16-8	2515-2518	and	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
16-9	2519-2523	gene	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
16-10	2524-2532	mutation	abstract[139]|abstract[142]|abstract	new[139]|giv[142]|giv	coref	16-38[155_0]
16-11	2533-2537	data	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
16-12	2538-2542	from	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
16-13	2543-2550	matched	abstract[139]|abstract[142]|object[146]	new[139]|giv[142]|giv[146]	_	_
16-14	2551-2557	cancer	abstract[139]|abstract[142]|abstract|object[146]	new[139]|giv[142]|giv|giv[146]	coref	19-21
16-15	2558-2562	cell	abstract[139]|abstract[142]|place|object[146]	new[139]|giv[142]|giv|giv[146]	_	_
16-16	2563-2568	lines	abstract[139]|abstract[142]|object[146]	new[139]|giv[142]|giv[146]	_	_
16-17	2569-2579	identified	_	_	_	_
16-18	2580-2585	known	abstract[148]	giv[148]	_	_
16-19	2586-2595	synthetic	abstract[148]	giv[148]	_	_
16-20	2596-2611	lethality-based	abstract[148]	giv[148]	_	_
16-21	2612-2616	drug	substance|abstract[148]	giv|giv[148]	coref	16-26[150_0]
16-22	2617-2624	targets	abstract[148]	giv[148]	_	_
16-23	2625-2629	like	abstract[148]	giv[148]	_	_
16-24	2630-2641	sensitivity	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-25	2642-2644	of	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-26	2645-2648	the	abstract[148]|abstract[149]|substance[150]	giv[148]|new[149]|giv[150]	coref	17-15[0_150]
16-27	2649-2653	drug	abstract[148]|abstract[149]|substance[150]	giv[148]|new[149]|giv[150]	_	_
16-28	2654-2655	,	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-29	2656-2664	olaparib	abstract[148]|abstract[149]|object	giv[148]|new[149]|new	_	_
16-30	2665-2666	(	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-31	2667-2671	PARP	abstract[148]|abstract[149]|abstract|person[153]	giv[148]|new[149]|new|new[153]	_	_
16-32	2672-2681	inhibitor	abstract[148]|abstract[149]|person[153]	giv[148]|new[149]|new[153]	_	_
16-33	2682-2683	)	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-34	2684-2686	in	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-35	2687-2690	the	abstract[148]|abstract[149]|abstract[154]	giv[148]|new[149]|new[154]	_	_
16-36	2691-2699	presence	abstract[148]|abstract[149]|abstract[154]	giv[148]|new[149]|new[154]	_	_
16-37	2700-2702	of	abstract[148]|abstract[149]|abstract[154]	giv[148]|new[149]|new[154]	_	_
16-38	2703-2711	mutation	abstract[148]|abstract[149]|abstract[154]|abstract[155]	giv[148]|new[149]|new[154]|giv[155]	_	_
16-39	2712-2714	in	abstract[148]|abstract[149]|abstract[154]|abstract[155]	giv[148]|new[149]|new[154]|giv[155]	_	_
16-40	2715-2718	the	abstract[148]|abstract[149]|abstract[154]|abstract[155]|abstract[157]	giv[148]|new[149]|new[154]|giv[155]|giv[157]	coref	17-10[163_157]
16-41	2719-2724	BRCA1	abstract[148]|abstract[149]|abstract[154]|abstract[155]|person|abstract[157]	giv[148]|new[149]|new[154]|giv[155]|new|giv[157]	_	_
16-42	2725-2729	gene	abstract[148]|abstract[149]|abstract[154]|abstract[155]|abstract[157]	giv[148]|new[149]|new[154]|giv[155]|giv[157]	_	_
16-43	2730-2731	,	abstract[148]|abstract[149]|abstract[154]	giv[148]|new[149]|new[154]	_	_
16-44	2732-2735	and	abstract[148]|abstract[149]|abstract[154]	giv[148]|new[149]|new[154]	_	_
16-45	2736-2738	in	abstract[148]|abstract[149]|abstract[154]	giv[148]|new[149]|new[154]	_	_
16-46	2739-2746	general	abstract[148]|abstract[149]|abstract[154]|person|place[161]	giv[148]|new[149]|new[154]|new|new[161]	_	_
16-47	2747-2750	the	abstract[148]|abstract[149]|abstract[154]|place[161]	giv[148]|new[149]|new[154]|new[161]	_	_
16-48	2751-2761	homologous	abstract[148]|abstract[149]|abstract[154]|place[161]	giv[148]|new[149]|new[154]|new[161]	_	_
16-49	2762-2775	recombination	abstract[148]|abstract[149]|abstract[154]|abstract|place[161]	giv[148]|new[149]|new[154]|new|new[161]	_	_
16-50	2776-2782	repair	abstract[148]|abstract[149]|abstract[154]|abstract|place[161]	giv[148]|new[149]|new[154]|new|new[161]	_	_
16-51	2783-2790	pathway	abstract[148]|abstract[149]|abstract[154]|place[161]	giv[148]|new[149]|new[154]|new[161]	_	_
16-52	2791-2792	.	_	_	_	_

#Text=In addition , the analysis offers to look into new potentially effective gene mutation-based drug therapies .
17-1	2793-2795	In	_	_	_	_
17-2	2796-2804	addition	_	_	_	_
17-3	2805-2806	,	_	_	_	_
17-4	2807-2810	the	abstract[162]	giv[162]	coref	18-3[168_162]
17-5	2811-2819	analysis	abstract[162]	giv[162]	_	_
17-6	2820-2826	offers	_	_	_	_
17-7	2827-2829	to	_	_	_	_
17-8	2830-2834	look	_	_	_	_
17-9	2835-2839	into	_	_	_	_
17-10	2840-2843	new	abstract[163]	giv[163]	coref	19-17[178_163]
17-11	2844-2855	potentially	abstract[163]	giv[163]	_	_
17-12	2856-2865	effective	abstract[163]	giv[163]	_	_
17-13	2866-2870	gene	abstract[163]	giv[163]	_	_
17-14	2871-2885	mutation-based	abstract[165]	new[165]	coref	22-14[213_165]
17-15	2886-2890	drug	substance|abstract[165]	giv|new[165]	coref	20-3
17-16	2891-2900	therapies	abstract[165]	new[165]	_	_
17-17	2901-2902	.	_	_	_	_

#Text=We extended our analysis to infer potential synergy between drugs targeting the predicted SL interactors .
18-1	2903-2905	We	person	giv	ana	18-3
18-2	2906-2914	extended	_	_	_	_
18-3	2915-2918	our	person|abstract[168]	giv|giv[168]	ana|ana	19-1|19-1
18-4	2919-2927	analysis	abstract[168]	giv[168]	_	_
18-5	2928-2930	to	_	_	_	_
18-6	2931-2936	infer	_	_	_	_
18-7	2937-2946	potential	abstract[169]	new[169]	_	_
18-8	2947-2954	synergy	abstract[169]	new[169]	_	_
18-9	2955-2962	between	abstract[169]	new[169]	_	_
18-10	2963-2968	drugs	abstract[169]|substance	new[169]|giv	coref	19-25[181_0]
18-11	2969-2978	targeting	_	_	_	_
18-12	2979-2982	the	abstract[172]	giv[172]	_	_
18-13	2983-2992	predicted	abstract[172]	giv[172]	_	_
18-14	2993-2995	SL	abstract|abstract[172]	giv|giv[172]	coref	19-29
18-15	2996-3007	interactors	abstract[172]	giv[172]	_	_
18-16	3008-3009	.	_	_	_	_

#Text=We reasoned that if the presence of a mutation ( or loss of function ) in a primary gene makes cancer cells sensitive to certain drugs targeting an SL interactor , then it is highly likely that the drugs targeting the primary gene will also make the cancer cells sensitive to those drugs targeting the SL interactor .
19-1	3010-3012	We	person	giv	ana	21-4
19-2	3013-3021	reasoned	_	_	_	_
19-3	3022-3026	that	_	_	_	_
19-4	3027-3029	if	_	_	_	_
19-5	3030-3033	the	abstract[174]	new[174]	_	_
19-6	3034-3042	presence	abstract[174]	new[174]	_	_
19-7	3043-3045	of	abstract[174]	new[174]	_	_
19-8	3046-3047	a	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-9	3048-3056	mutation	abstract[174]|abstract[175]	new[174]|new[175]	_	_
19-10	3057-3058	(	abstract[174]	new[174]	_	_
19-11	3059-3061	or	abstract[174]	new[174]	_	_
19-12	3062-3066	loss	abstract[174]|abstract[176]	new[174]|new[176]	_	_
19-13	3067-3069	of	abstract[174]|abstract[176]	new[174]|new[176]	_	_
19-14	3070-3078	function	abstract[174]|abstract[176]|abstract	new[174]|new[176]|new	_	_
19-15	3079-3080	)	abstract[174]	new[174]	_	_
19-16	3081-3083	in	_	_	_	_
19-17	3084-3085	a	abstract[178]	giv[178]	coref	19-41[186_178]
19-18	3086-3093	primary	abstract[178]	giv[178]	_	_
19-19	3094-3098	gene	abstract[178]	giv[178]	_	_
19-20	3099-3104	makes	_	_	_	_
19-21	3105-3111	cancer	abstract|object[180]	giv|giv[180]	coref|coref|coref|coref	19-48|19-47[189_180]|19-48|19-47[189_180]
19-22	3112-3117	cells	object[180]	giv[180]	_	_
19-23	3118-3127	sensitive	object[180]	giv[180]	_	_
19-24	3128-3130	to	_	_	_	_
19-25	3131-3138	certain	substance[181]	giv[181]	coref	19-38[185_181]
19-26	3139-3144	drugs	substance[181]	giv[181]	_	_
19-27	3145-3154	targeting	_	_	_	_
19-28	3155-3157	an	abstract[183]	new[183]	coref	19-55[192_183]
19-29	3158-3160	SL	abstract|abstract[183]	giv|new[183]	coref	19-56
19-30	3161-3171	interactor	abstract[183]	new[183]	_	_
19-31	3172-3173	,	_	_	_	_
19-32	3174-3178	then	_	_	_	_
19-33	3179-3181	it	event	new	cata	19-33[0_187]
19-34	3182-3184	is	_	_	_	_
19-35	3185-3191	highly	_	_	_	_
19-36	3192-3198	likely	_	_	_	_
19-37	3199-3203	that	event[187]	new[187]	_	_
19-38	3204-3207	the	substance[185]|event[187]	giv[185]|new[187]	coref	19-52[190_185]
19-39	3208-3213	drugs	substance[185]|event[187]	giv[185]|new[187]	_	_
19-40	3214-3223	targeting	event[187]	new[187]	_	_
19-41	3224-3227	the	abstract[186]|event[187]	giv[186]|new[187]	_	_
19-42	3228-3235	primary	abstract[186]|event[187]	giv[186]|new[187]	_	_
19-43	3236-3240	gene	abstract[186]|event[187]	giv[186]|new[187]	_	_
19-44	3241-3245	will	event[187]	new[187]	_	_
19-45	3246-3250	also	event[187]	new[187]	_	_
19-46	3251-3255	make	event[187]	new[187]	_	_
19-47	3256-3259	the	event[187]|object[189]	new[187]|giv[189]	_	_
19-48	3260-3266	cancer	event[187]|abstract|object[189]	new[187]|giv|giv[189]	_	_
19-49	3267-3272	cells	event[187]|object[189]	new[187]|giv[189]	_	_
19-50	3273-3282	sensitive	event[187]|object[189]	new[187]|giv[189]	_	_
19-51	3283-3285	to	_	_	_	_
19-52	3286-3291	those	substance[190]	giv[190]	coref	21-7[202_190]
19-53	3292-3297	drugs	substance[190]	giv[190]	_	_
19-54	3298-3307	targeting	_	_	_	_
19-55	3308-3311	the	abstract[192]	giv[192]	_	_
19-56	3312-3314	SL	abstract|abstract[192]	giv|giv[192]	_	_
19-57	3315-3325	interactor	abstract[192]	giv[192]	_	_
19-58	3326-3327	.	_	_	_	_

#Text=These inferred drug synergies can be searched in SL-BioDP for each of the 18 tumor histologies included in SL-BioDP .
20-1	3328-3333	These	abstract[194]	new[194]	_	_
20-2	3334-3342	inferred	abstract[194]	new[194]	_	_
20-3	3343-3347	drug	substance|abstract[194]	giv|new[194]	_	_
20-4	3348-3357	synergies	abstract[194]	new[194]	_	_
20-5	3358-3361	can	_	_	_	_
20-6	3362-3364	be	_	_	_	_
20-7	3365-3373	searched	_	_	_	_
20-8	3374-3376	in	_	_	_	_
20-9	3377-3385	SL-BioDP	abstract	giv	coref	20-19
20-10	3386-3389	for	_	_	_	_
20-11	3390-3394	each	_	_	_	_
20-12	3395-3397	of	_	_	_	_
20-13	3398-3401	the	abstract[197]	new[197]	_	_
20-14	3402-3404	18	abstract[197]	new[197]	_	_
20-15	3405-3410	tumor	abstract|abstract[197]	giv|new[197]	_	_
20-16	3411-3422	histologies	abstract[197]	new[197]	_	_
20-17	3423-3431	included	_	_	_	_
20-18	3432-3434	in	_	_	_	_
20-19	3435-3443	SL-BioDP	abstract	giv	coref	22-4
20-20	3444-3445	.	_	_	_	_

#Text=In support of our predictions of synergistic drugs in cancers , we collected literature references and reports of ongoing clinical trials , which is included in Supplementary Table S3 .
21-1	3446-3448	In	_	_	_	_
21-2	3449-3456	support	abstract[199]	new[199]	_	_
21-3	3457-3459	of	abstract[199]	new[199]	_	_
21-4	3460-3463	our	abstract[199]|person|abstract[201]	new[199]|giv|new[201]	ana|ana	21-12|21-12
21-5	3464-3475	predictions	abstract[199]|abstract[201]	new[199]|new[201]	_	_
21-6	3476-3478	of	abstract[199]|abstract[201]	new[199]|new[201]	_	_
21-7	3479-3490	synergistic	abstract[199]|abstract[201]|substance[202]	new[199]|new[201]|giv[202]	_	_
21-8	3491-3496	drugs	abstract[199]|abstract[201]|substance[202]	new[199]|new[201]|giv[202]	_	_
21-9	3497-3499	in	abstract[199]|abstract[201]|substance[202]	new[199]|new[201]|giv[202]	_	_
21-10	3500-3507	cancers	abstract[199]|abstract[201]|substance[202]|abstract	new[199]|new[201]|giv[202]|giv	_	_
21-11	3508-3509	,	_	_	_	_
21-12	3510-3512	we	person	giv	_	_
21-13	3513-3522	collected	_	_	_	_
21-14	3523-3533	literature	abstract|abstract[206]	giv|new[206]	_	_
21-15	3534-3544	references	abstract[206]	new[206]	_	_
21-16	3545-3548	and	_	_	_	_
21-17	3549-3556	reports	abstract	new	_	_
21-18	3557-3559	of	_	_	_	_
21-19	3560-3567	ongoing	_	_	_	_
21-20	3568-3576	clinical	abstract[208]	new[208]	_	_
21-21	3577-3583	trials	abstract[208]	new[208]	_	_
21-22	3584-3585	,	_	_	_	_
21-23	3586-3591	which	_	_	_	_
21-24	3592-3594	is	_	_	_	_
21-25	3595-3603	included	_	_	_	_
21-26	3604-3606	in	_	_	_	_
21-27	3607-3620	Supplementary	event|abstract[211]	new|new[211]	_	_
21-28	3621-3626	Table	abstract|abstract[211]	new|new[211]	_	_
21-29	3627-3629	S3	abstract[211]	new[211]	_	_
21-30	3630-3631	.	_	_	_	_

#Text=Combined together , SL-BioDP can serve as a comprehensive tool , for exploring potentially actionable mutation-based targeted therapies based on the concept of synthetic lethality , that shows possible clinical relevance .
22-1	3632-3640	Combined	_	_	_	_
22-2	3641-3649	together	_	_	_	_
22-3	3650-3651	,	_	_	_	_
22-4	3652-3660	SL-BioDP	abstract	giv	_	_
22-5	3661-3664	can	_	_	_	_
22-6	3665-3670	serve	_	_	_	_
22-7	3671-3673	as	_	_	_	_
22-8	3674-3675	a	_	_	_	_
22-9	3676-3689	comprehensive	_	_	_	_
22-10	3690-3694	tool	_	_	_	_
22-11	3695-3696	,	_	_	_	_
22-12	3697-3700	for	_	_	_	_
22-13	3701-3710	exploring	_	_	_	_
22-14	3711-3722	potentially	abstract[213]	giv[213]	_	_
22-15	3723-3733	actionable	abstract[213]	giv[213]	_	_
22-16	3734-3748	mutation-based	abstract[213]	giv[213]	_	_
22-17	3749-3757	targeted	abstract[213]	giv[213]	_	_
22-18	3758-3767	therapies	abstract[213]	giv[213]	_	_
22-19	3768-3773	based	_	_	_	_
22-20	3774-3776	on	_	_	_	_
22-21	3777-3780	the	abstract[214]	giv[214]	_	_
22-22	3781-3788	concept	abstract[214]	giv[214]	_	_
22-23	3789-3791	of	abstract[214]	giv[214]	_	_
22-24	3792-3801	synthetic	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
22-25	3802-3811	lethality	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
22-26	3812-3813	,	_	_	_	_
22-27	3814-3818	that	_	_	_	_
22-28	3819-3824	shows	_	_	_	_
22-29	3825-3833	possible	abstract[216]	giv[216]	_	_
22-30	3834-3842	clinical	abstract[216]	giv[216]	_	_
22-31	3843-3852	relevance	abstract[216]	giv[216]	_	_
22-32	3853-3854	.	_	_	_	_
